Latest / Breastcancer.org Podcast

Experimental Capivasertib Seems Promising for Advanced-Stage, Hormone Receptor-Positive, HER2-Negative Breast Cancer
Researchers are always looking for new treatments for advanced-stage breast cancer. Dr. Nicholas Turner explains the results of the CAPitello-291 trial, looking capivasertib, an experimental targeted therapy medicine, in combination with Faslodex (chemical name: fulvestrant) as a treatment for advanced-stage, hormone receptor-positive, HER2-negative breast cancer that has become resistant to the aromatase inhibitors.
Listen to the episode to hear Dr. Turner explain:
how capivasertib works
the results of the CAPitello-291 trial
how capivasertib worked on cancers previously treated with a…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.